NCT05030675View on ClinicalTrials.gov

Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 13, 2021

Primary Completion Date

August 8, 2024

Study Completion Date

August 8, 2024

Conditions
Refractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic Syndrome
Interventions
DRUG

Fostamatinib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT05030675 - Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents | Biotech Hunter | Biotech Hunter